$OTLC
Oncotelic Therapeutics, Inc.

2015 Q2 Form 10-Q Financial Statement

#000119312515176991 Filed on May 07, 2015

View on sec.gov

Income Statement

Concept 2015 Q2 2015 Q1 2014 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.350M $1.110M $1.040M
YoY Change -22.86% -10.48% 6.12%
% of Gross Profit
Research & Development $1.981M $1.669M $1.610M
YoY Change -8.75% 20.33% 43.75%
% of Gross Profit
Depreciation & Amortization $0.00 $5.000K $30.00K
YoY Change -100.0% 25.0% 0.0%
% of Gross Profit
Operating Expenses $3.328M $2.777M $2.650M
YoY Change -15.19% 5.67% 26.19%
Operating Profit -$3.328M -$2.777M
YoY Change -15.19% 5.67%
Interest Expense $10.00K $0.00 $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net -$1.000K $2.000K $10.00K
YoY Change -83.33% -166.67%
Pretax Income -$3.320M -$2.770M -$2.640M
YoY Change -15.52% 5.32% 25.71%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$3.324M -$2.772M -$2.640M
YoY Change -15.4% 5.4% 25.71%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$0.13 -$0.13 -$0.13
COMMON SHARES
Basic Shares Outstanding 26.54M shares 26.54M shares 20.71M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q2 2015 Q1 2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $33.09M $35.74M $30.03M
YoY Change -8.77% 44.46% 328.39%
Cash & Equivalents $33.09M $35.74M $30.03M
Short-Term Investments
Other Short-Term Assets $470.0K $760.0K $4.000K
YoY Change 2511.11% 1753.66% -94.03%
Inventory
Prepaid Expenses $755.0K $318.0K
Receivables
Other Receivables
Total Short-Term Assets $33.56M $36.49M $30.35M
YoY Change -8.64% 45.12% 323.63%
LONG-TERM ASSETS
Property, Plant & Equipment $42.00K $32.00K $37.00K
YoY Change 50.0% 0.0% 2.78%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $33.00K $33.00K $33.00K
YoY Change 0.0%
Total Long-Term Assets $75.00K $65.00K $70.00K
YoY Change -30.56% -36.27% -45.74%
TOTAL ASSETS
Total Short-Term Assets $33.56M $36.49M $30.35M
Total Long-Term Assets $75.00K $65.00K $70.00K
Total Assets $33.64M $36.56M $30.42M
YoY Change -8.71% 44.8% 317.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $178.0K $189.0K $335.0K
YoY Change -79.03% -56.25% -29.62%
Accrued Expenses $990.0K $840.0K $1.080M
YoY Change -10.0% -12.5% 38.46%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.166M $1.029M $1.419M
YoY Change -40.14% -26.24% 13.43%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.166M $1.029M $1.419M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.170M $1.030M $1.420M
YoY Change -40.0% -26.43% 13.6%
SHAREHOLDERS EQUITY
Retained Earnings -$257.3M -$253.9M -$251.2M
YoY Change 4.97% 5.3% 5.3%
Common Stock $289.7M $289.5M $280.2M
YoY Change 3.49% 9.23% 14.56%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $32.47M $35.53M $29.00M
YoY Change
Total Liabilities & Shareholders Equity $33.64M $36.56M $30.42M
YoY Change -8.71% 44.8% 317.1%

Cashflow Statement

Concept 2015 Q2 2015 Q1 2014 Q4
OPERATING ACTIVITIES
Net Income -$3.324M -$2.772M -$2.640M
YoY Change -15.4% 5.4% 25.71%
Depreciation, Depletion And Amortization $0.00 $5.000K $30.00K
YoY Change -100.0% 25.0% 0.0%
Cash From Operating Activities -$2.620M -$3.500M -$2.840M
YoY Change -20.85% 33.38% 33.33%
INVESTING ACTIVITIES
Capital Expenditures $20.00K $10.00K
YoY Change -75.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$20.00K -$10.00K
YoY Change -75.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $9.207M
YoY Change -15.22%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -10.00K 9.210M 0.000
YoY Change -100.07% -54.75% -100.0%
NET CHANGE
Cash From Operating Activities -2.620M -3.500M -2.840M
Cash From Investing Activities -20.00K -10.00K
Cash From Financing Activities -10.00K 9.210M 0.000
Net Change In Cash -2.650M 5.710M -2.850M
YoY Change -122.98% -67.79% 61.02%
FREE CASH FLOW
Cash From Operating Activities -$2.620M -$3.500M -$2.840M
Capital Expenditures $20.00K $10.00K
Free Cash Flow -$2.640M -$2.850M
YoY Change 31.34%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
26544934 shares
CY2015Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.7125
CY2015Q1 oxgn Threshold Limit Percentage On Warrants Owned
ThresholdLimitPercentageOnWarrantsOwned
0.0499 pure
CY2014Q1 us-gaap Cash
Cash
24735000
CY2015Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26545000 shares
CY2015Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26545000 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
585000 shares
CY2015Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
70000000 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.57
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
272000 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.50
CY2015Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
10599000 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
3.67
CY2015Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2015Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000 shares
CY2015Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2015Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
689000 shares
CY2015Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
247000
CY2015Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1029000
CY2015Q1 us-gaap Common Stock Value
CommonStockValue
265000
CY2015Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
189000
CY2015Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-253927000
CY2015Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
289188000
CY2015Q1 us-gaap Stockholders Equity
StockholdersEquity
35526000
CY2015Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
202000
CY2015Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
36555000
CY2015Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
414000
CY2015Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
560000
CY2015Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
32000
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2015Q1 us-gaap Assets
Assets
36555000
CY2015Q1 us-gaap Cash
Cash
35735000
CY2015Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
33000
CY2015Q1 us-gaap Assets Current
AssetsCurrent
36490000
CY2015Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
755000
CY2015Q1 oxgn Purchase Commitment Amount Due
PurchaseCommitmentAmountDue
4100000
CY2015Q1 oxgn Purchase Commitment Estimated And Accrued
PurchaseCommitmentEstimatedAndAccrued
73000
CY2015Q1 oxgn Accrued Research And Development
AccruedResearchAndDevelopment
224000
CY2015Q1 oxgn Future Purchase Commitment
FuturePurchaseCommitment
2303000
CY2013Q4 us-gaap Cash
Cash
7005000
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20705000 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20705000 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
70000000 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.63
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
7445000 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000 shares
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
672000 shares
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
242000
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1419000
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
2628000
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1387000
CY2014Q1 us-gaap Adjustment For Amortization
AdjustmentForAmortization
23000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
207000
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
17730000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
335000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-251155000
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
279952000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
29004000
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
207000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
30423000
CY2014Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
841000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
37000
CY2014Q4 us-gaap Assets
Assets
30423000
CY2014Q4 us-gaap Cash
Cash
30031000
CY2014Q4 us-gaap Other Assets Current
OtherAssetsCurrent
4000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
33000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
30353000
CY2014Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
318000
CY2014Q4 oxgn Accrued Research And Development
AccruedResearchAndDevelopment
36000
CY2015Q1 oxgn Proceeds From Issuance Of Common Stock And Warrants In Offering Gross
ProceedsFromIssuanceOfCommonStockAndWarrantsInOfferingGross
10000000
CY2015Q1 oxgn Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
9207000
CY2015Q1 oxgn Class Of Warrant Or Right Term
ClassOfWarrantOrRightTerm
P5Y
CY2015Q1 oxgn Increase In Threshold Limit Percentage On Warrants Owned
IncreaseInThresholdLimitPercentageOnWarrantsOwned
0.0999 pure
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2624000
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9054000 shares
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
CY2014Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
249000
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2628000
CY2014Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3000
CY2014Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-2630000
CY2014Q1 us-gaap Depreciation
Depreciation
4000
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
20354000
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10860000
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1241000
CY2014Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
144000
CY2014Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
9494000
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
84000
CY2015Q1 dei Document Type
DocumentType
10-Q
CY2015Q1 dei Entity Registrant Name
EntityRegistrantName
OXIGENE INC
CY2015Q1 dei Trading Symbol
TradingSymbol
OXGN
CY2015Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2015Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y6M
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3503000
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
25000 shares
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P8Y1M24D
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0147 pure
CY2015Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> <b><i><u>Use of Estimates</u></i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in conformity with U.S.&#xA0;generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates.</p> </div>
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
21095000 shares
CY2015Q1 dei Document Period End Date
DocumentPeriodEndDate
2015-03-31
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
3.28
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y5M27D
CY2015Q1 dei Amendment Flag
AmendmentFlag
false
CY2015Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y22D
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
8000 shares
CY2015Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.74
CY2015Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000908259
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9450 pure
CY2015Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
434000
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2777000
CY2015Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000
CY2015Q1 us-gaap Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
4027000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-2772000
CY2015Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
3000
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
2777000
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1669000
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
5704000
CY2015Q1 us-gaap Depreciation
Depreciation
5000
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
9207000
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9207000
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1108000
CY2015Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-390000
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
88000
CY2015Q1 oxgn Number Of Drug Candidates
NumberOfDrugCandidates
2 Candidate
CY2015Q1 oxgn Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term Two
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermTwo
P8Y3M18D

Files In Submission

Name View Source Status
0001193125-15-176991-index-headers.html Edgar Link pending
0001193125-15-176991-index.html Edgar Link pending
0001193125-15-176991.txt Edgar Link pending
0001193125-15-176991-xbrl.zip Edgar Link pending
d899068d10q.htm Edgar Link pending
d899068dex311.htm Edgar Link pending
d899068dex312.htm Edgar Link pending
d899068dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
oxgn-20150331.xml Edgar Link completed
oxgn-20150331.xsd Edgar Link pending
oxgn-20150331_cal.xml Edgar Link unprocessable
oxgn-20150331_def.xml Edgar Link unprocessable
oxgn-20150331_lab.xml Edgar Link unprocessable
oxgn-20150331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending